Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;30(3):249-65.
doi: 10.1385/JMN:30:3:249.

Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging

Affiliations
Review

Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging

Marie-Pierre Hinault et al. J Mol Neurosci. 2006.

Abstract

The formation of toxic protein aggregates is a common denominator to many neurodegenerative diseases and aging. Accumulation of toxic, possibly infectious protein aggregates induces a cascade of events, such as excessive inflammation, the production of reactive oxygen species, apoptosis and neuronal loss. A network of highly conserved molecular chaperones and of chaperone-related proteases controls the fold-quality of proteins in the cell. Most molecular chaperones can passively prevent protein aggregation by binding misfolding intermediates. Some molecular chaperones and chaperone-related proteases, such as the proteasome, can also hydrolyse ATP to forcefully convert stable harmful protein aggregates into harmless natively refoldable, or protease-degradable, polypeptides. Molecular chaperones and chaperone-related proteases thus control the delicate balance between natively folded functional proteins and aggregation-prone misfolded proteins, which may form during the lifetime and lead to cell death. Abundant data now point at the molecular chaperones and the proteases as major clearance mechanisms to remove toxic protein aggregates from cells, delaying the onset and the outcome of protein-misfolding diseases. Therapeutic approaches include treatments and drugs that can specifically induce and sustain a strong chaperone and protease activity in cells and tissues prone to toxic protein aggregations.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Biochem Biophys Res Commun. 2003 Aug 1;307(3):689-95 - PubMed
    1. Nat Cell Biol. 2000 Aug;2(8):476-83 - PubMed
    1. Expert Opin Ther Targets. 2005 Oct;9(5):887-900 - PubMed
    1. J Biol Chem. 1996 Mar 22;271(12):6839-44 - PubMed
    1. J Neurochem. 2005 Nov;95(4):950-61 - PubMed

Publication types

MeSH terms

LinkOut - more resources